Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Genitourinary 2CNS 2Gastrointestinal 1Endocrine 1

Conditions

Brain Neoplasms 7Carcinoma, Renal Cell 4Glioblastoma 3Central Nervous System Neoplasms 3Carcinoma, Medullary 3Wilms Tumor 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Pheochromocytoma 2Paraganglioma 2Osteosarcoma 2Neurofibroma, Plexiform 2Glioma 2Astrocytoma 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Rhabdoid Tumor 1Paraganglioma, Extra-Adrenal 1Neurofibromatosis 1 1Neurofibromatoses 1Neuroendocrine Tumors 1Neuroblastoma 1Meningioma 1Melanoma 1Lung Neoplasms 1Hepatoblastoma 1

Interventions

Temozolomide 8Irinotecan 7Melphalan 6Cyclophosphamide 6X-Rays 5Topotecan 5Phantoms, Imaging 5Magnetic Resonance Spectroscopy 5Granulocyte Colony-Stimulating Factor 5Specimen Handling 4Nuclear Medicine Department, Hospital 4Busulfan 4palbociclib 3fludarabine 3Vincristine 3Thiotepa 3Stem Cell Transplantation 3Sirolimus 3Nivolumab 3Etoposide 3Bone Marrow Transplantation 3Biopsy 3ulixertinib 2tipifarnib 2thymoglobulin 2tazemetostat 2selpercatinib 2omburtamab I-131 2olaparib 2larotrectinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Rhabdomyosarcoma × cabozantinib × CNS × Clear all
NCT02867592 2026-06-11

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
109 enrolled 24 charts
CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Adrenocortical Carcinoma, Carcinoma, Medullary

NCT05135975 2025-08-12

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

Nationwide Children's Hospital

Phase 2 Recruiting
86 enrolled
CNSGenitourinarySarcoma

Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡